lyophilized powder raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; may appear as cake |
| Solubility class | Water-soluble | Often reconstituted in aqueous buffer |
| Typical storage temperature | −20 °C or below | Protect from light and moisture |
| Typical analytical method | RP-HPLC and mass spectrometry | Used for purity and identity |
| Common synonyms | AOD-9604; AOD9604; hGH fragment 176-191 | Research name and fragment description |
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Treatment of electron beams is created as a result of high energy electrons in an accelerator that generates electrons accelerated to 99% the speed of light. This system uses electrical energy and can be powered on and off. The high power correlates with a higher throughput and lower unit cost, but electron beams have low dose uniformity and a penetration depth of centimeters. Therefore, electron beam treatment works for products that have low thickness.
== Structure == The thermodynamically stable form of CaCO3 under normal conditions is hexagonal β-CaCO3 (the mineral calcite). Other forms can be prepared, the denser (2.83 g/cm3) orthorhombic λ-CaCO3 (the mineral aragonite) and hexagonal μ-CaCO3, occurring as the mineral vaterite. The aragonite form can be prepared by precipitation at temperatures above 85 °C; the vaterite form can be prepared by precipitation at 60 °C. Calcite contains calcium atoms coordinated by six oxygen atoms; in aragonite they are coordinated by nine oxygen atoms. The vaterite structure is not fully understood. Magnesium carbonate (MgCO3) has the calcite structure, whereas strontium carbonate (SrCO3) and barium carbonate (BaCO3) adopt the aragonite structure, reflecting their larger ionic radii.
In Italy, Gasparo Tagliacozzi (1546–1599), professor of surgery and anatomy at the University of Bologna, published Curtorum Chirurgia Per Insitionem (The Surgery of Defects by Implantations, 1597), a technico–procedural manual for the surgical repair and reconstruction of facial wounds in soldiers. The illustrations featured a re-attachment rhinoplasty using a biceps muscle pedicle flap; the graft attached at 3-weeks post-procedure; which, at 2-weeks post-attachment, the surgeon then shaped into a nose. In Great Britain, Joseph Constantine Carpue (1764–1846) published the descriptions of two rhinoplasties: the reconstruction of a battle-wounded nose, and the repair of an arsenic-damaged nose. (cf. Carpue's operation).
Cool store — a large refrigerated room or building Cool warehouse — a very large refrigerated building Silo — used to store grains, like wheat and maize 2800 Polar Way — world's largest food freezer Controlled atmosphere storage — commercial facilities that regulate oxygen, carbon dioxide, and humidity to slow ripening and spoilage of fruits, extending storage life.
=== Mustelidae (Weasels) === Mustela nigripes, Black-footed ferret Gulo gulo, Wolverine (first attributed to the putative extinct subspecies G. g. berelekhii, which is probably a junior synonym of the extant subspecies G. g. jacutensis)
Sources: en.wikipedia.org
==== MeSH D13.695.827 – ribonucleotides ==== MeSH D13.695.827.068 – adenine nucleotides MeSH D13.695.827.068.124 – adenosine diphosphate MeSH D13.695.827.068.124.070 – adenosine diphosphate sugars MeSH D13.695.827.068.124.070.075 – adenosine diphosphate glucose MeSH D13.695.827.068.124.070.125 – adenosine diphosphate ribose MeSH D13.695.827.068.124.070.125.040 – o-acetyl-adp-ribose MeSH D13.695.827.068.124.070.125.195 – cyclic adp-ribose MeSH D13.695.827.068.180 – adenosine monophosphate MeSH D13.695.827.068.180.080 – adenosine phosphosulfate MeSH D13.695.827.068.236 – adenosine triphosphate MeSH D13.695.827.068.236.050 – adenylyl imidodiphosphate MeSH D13.695.827.068.236.250 – ethenoadenosine triphosphate MeSH D13.695.827.068.382 – coenzyme a MeSH D13.695.827.068.382.300 – acyl coenzyme a MeSH D13.695.827.068.382.300.020 – acetyl coenzyme a MeSH D13.695.827.068.382.300.500 – malonyl coenzyme a MeSH D13.695.827.068.382.300.700 – palmitoyl coenzyme a MeSH D13.695.827.068.395 – cyclic amp MeSH D13.695.827.068.395.225 – 8-bromo cyclic adenosine monophosphate MeSH D13.695.827.068.395.250 – bucladesine MeSH D13.695.827.068.506 – flavin-adenine dinucleotide MeSH D13.695.827.068.694 – nad MeSH D13.695.827.068.749 – nadp MeSH D13.695.827.068.850 – phosphoadenosine phosphosulfate MeSH D13.695.827.232 – cytosine nucleotides MeSH D13.695.827.232.115 – cyclic cmp MeSH D13.695.827.232.150 – cytidine diphosphate MeSH D13.695.827.232.150.180 – cytidine diphosphate choline MeSH D13.695.827.232.150.210 – cytidine diphosphate diglycerides MeSH D13.695.827.232.370 – cytidine monophosphate MeSH D13.695.827.232.370.250 – cytidine monophosphate n-acetylneuraminic acid MeSH D13.695.827.232.400 – cytidine triphosphate MeSH D13.695.827.349 – flavin mononucleotide MeSH D13.695.827.426 – guanine nucleotides MeSH D13.695.827.426.160 – cyclic gmp MeSH D13.695.827.426.160.325 – dibutyryl cyclic gmp MeSH D13.695.827.426.340 – guanosine diphosphate MeSH D13.695.827.426.340.350 – guanosine diphosphate sugars MeSH D13.695.827.426.340.350.400 – guanosine diphosphate fucose MeSH D13.695.827.426.340.350.500 – guanosine diphosphate mannose MeSH D13.695.827.426.440 – guanosine pentaphosphate MeSH D13.695.827.426.480 – guanosine tetraphosphate MeSH D13.695.827.426.504 – guanosine triphosphate MeSH D13.695.827.426.504.380 – guanosine 5'-o-(3-thiotriphosphate) MeSH D13.695.827.426.504.400 – guanylyl imidodiphosphate MeSH D13.695.827.426.525 – 5'-guanylic acid MeSH D13.695.827.426.700 – rna caps MeSH D13.695.827.426.700.710 – rna cap analogs MeSH D13.695.827.519 – inosine nucleotides MeSH D13.695.827.519.300 – cyclic imp MeSH D13.695.827.519.400 – inosine diphosphate MeSH D13.695.827.519.500 – inosine monophosphate MeSH D13.695.827.519.800 – inosine triphosphate MeSH D13.695.827.648 – nicotinamide mononucleotide MeSH D13.695.827.708 – nucleoside diphosphate sugars MeSH D13.695.827.708.070 – adenosine diphosphate sugars MeSH D13.695.827.708.070.075 – adenosine diphosphate glucose MeSH D13.695.827.708.070.125 – adenosine diphosphate ribose MeSH D13.695.827.708.070.125.040 – o-acetyl-adp-ribose MeSH D13.695.827.708.070.125.195 – cyclic adp-ribose MeSH D13.695.827.708.070.125.600 – poly adenosine diphosphate ribose MeSH D13.695.827.708.260 – cytidine diphosphate diglycerides MeSH D13.695.827.708.400 – guanosine diphosphate sugars MeSH D13.695.827.708.400.410 – guanosine diphosphate fucose MeSH D13.695.827.708.400.500 – guanosine diphosphate mannose MeSH D13.695.827.708.727 – uridine diphosphate sugars MeSH D13.695.827.708.727.100 – uridine diphosphate n-acetylgalactosamine MeSH D13.695.827.708.727.120 – uridine diphosphate n-acetylglucosamine MeSH D13.695.827.708.727.150 – uridine diphosphate n-acetylmuramic acid MeSH D13.695.827.708.727.300 – uridine diphosphate galactose MeSH D13.695.827.708.727.350 – uridine diphosphate glucose MeSH D13.695.827.708.727.375 – uridine diphosphate glucuronic acid MeSH D13.695.827.708.727.800 – uridine diphosphate xylose MeSH D13.695.827.919 – uracil nucleotides MeSH D13.695.827.919.600 – uridine diphosphate MeSH D13.695.827.919.600.677 – uridine diphosphate sugars MeSH D13.695.827.919.600.677.100 – uridine diphosphate n-acetylgalactosamine MeSH D13.695.827.919.600.677.120 – uridine diphosphate n-acetylglucosamine MeSH D13.695.827.919.600.677.150 – uridine diphosphate n-acetylmuramic acid MeSH D13.695.827.919.600.677.300 – uridine diphosphate galactose MeSH D13.695.827.919.600.677.350 – uridine diphosphate glucose MeSH D13.695.827.919.600.677.375 – uridine diphosphate glucuronic acid MeSH D13.695.827.919.600.677.800 – uridine diphosphate xylose MeSH D13.695.827.919.877 – uridine monophosphate MeSH D13.695.827.919.950 – uridine triphosphate
== Cap snatching in Arenaviridae and Bunyavirales == The family Arenaviridae and order Bunyavirales are also segmented negative, single-stranded RNA viruses. A verified Mn2+ dependent endonuclease is located at the N-terminus of the L protein. TN-terminal domain is conserved between various families, suggesting evolutionary similarity. However, the cap-binding domain is not confirmed for every virus family, but it is believed to be located in the L or nucleocapsid (N or NP) protein.[1] In the bunyavirales, endonuclease cleavage and nucleotide motif preferences vary between families, genera and species. This variation occurs because of a need to some base pairing with the 3' end of the viral genome. The nucleoprotein structure in Lassa virus (Arenaviridae) contains a second nuclease. Researchers propose that it is involved in attenuating interferon response, but it also contains a dTTP-binding site which may be used for cap-snatching. In this model, the L and N proteins cooperate in the cap-snatching process. The two-domain model has also been prosed for hantaviruses, but the N protein in the rift valley fever virus (Phenuiviridae) does not possess the same features.
=== Use in supplements aimed at eye health === In 2013, the Age-Related Eye Disease Study 2 (AREDS2) reported a reduced risk of visual loss and a reduced risk of disease progression over 5 years in 4,200 participants with early or moderate age-related macular degeneration (AMD) who were supplemented with a formulation containing the macular carotenoids and co-antioxidants. The AREDS2 preparation contained only two of the macular pigment’s three carotenoids (lutein and 3R,3´R-zeaxanthin), and did not include meso-zeaxanthin, which is the dominant carotenoid at the centre of the macula, the presence of which is essential for maximum collective antioxidant effect. Studies have shown that the addition of meso-zeaxanthin to formulations used to increase MP and enhance visual function in diseased and healthy retinas has proven effective. Trials have shown that a formulation containing all three macular carotenoids in a meso-zeaxanthin:lutein:zeaxanthin (mg) ratio of 10:10:2 is superior to alternative formulations, in terms of visual improvements and in observed increases in MP.
== Further reading == Andrew H. Cutler, Metallurgical Properties of Lunar and Asteroidal Steels, 7th Princeton/AIAA/SSI Conference, 1985. David Gump, Space Enterprise: Beyond NASA, Praeger Publishers, 1990, ISBN 0-275-93314-8. T. A. Heppenheimer, Colonies in Space, 1977, Stackpole Books, ISBN 0-8117-0397-5. Lewis, J., Matthews, M.S., and Guerrieri, M.L., Editors, 1993, Resources of Near-Earth Space, University of Arizona Press, 1993. ISBN 978-0-8165-1404-5. Wahl, Bruno W. (1968). Analysis of Selected Opportunities for Manufacturing in Space. McDonald Douglas Astronautics Company.
Sources: en.wikipedia.org
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.
Reversed-phase HPLC and mass spectrometry are standard checks. They confirm peptide purity and molecular mass, but they do not by themselves demonstrate biological activity.
Synthesis, purification, and handling conditions can differ, leading to variations in purity and salt content. Certificates of analysis help, but independent testing is often needed for verification.
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.